In vivo imaging of nanoparticle-labeled CAR T cells

Metastatic osteosarcoma has a poor prognosis with a 2-y, event-free survival rate of ∼15 to 20%, highlighting the need for the advancement of efficacious therapeutics. Chimeric antigen receptor (CAR) T-cell therapy is a potent strategy for eliminating tumors by harnessing the immune system. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiru, Louise, Zlitni, Aimen, Tousley, Aidan Michael, Dalton, Guillermo Nicolás, Wu, Wei, Lafortune, Famyrah, Liu, Anna, Cunanan, Kristen May, Nejadnik, Hossein, Sulchek, Todd, Moseley, Michael Eugene, Majzner, Robbie G., Daldrup-Link, Heike Elisabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2022
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832996/
https://www.ncbi.nlm.nih.gov/pubmed/35101971
http://dx.doi.org/10.1073/pnas.2102363119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832996/
https://www.ncbi.nlm.nih.gov/pubmed/35101971
http://dx.doi.org/10.1073/pnas.2102363119

Ejemplares similares